Recommendations for optimising the treatment of multiple sclerosis in Latin America

dc.contributor.authorCristiano, E.
dc.contributor.authorArcega Revilla, Raúl
dc.contributor.authorCorreale, J.
dc.contributor.authorGabbai, Alberto Alain [UNIFESP]
dc.contributor.authorLander-Delgado, R.
dc.contributor.authorMacias-Islas, M. A.
dc.contributor.authorPalacios, E.
dc.contributor.authorPatrucco, L.
dc.contributor.authorRivera-Olmos, Victor Manuel
dc.contributor.authorSoto, A.
dc.contributor.institutionHosp Italiano Buenos Aires
dc.contributor.institutionFLENI
dc.contributor.institutionIMSS
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHosp Domingo Luciani
dc.contributor.institutionHosp San Jose de Bogota
dc.contributor.institutionBaylor Coll Med
dc.date.accessioned2018-06-18T11:48:33Z
dc.date.available2018-06-18T11:48:33Z
dc.date.issued2007-04-16
dc.description.abstractIntroduction. Multiple sclerosis (MS) is the most common primary demyelinating disease affecting the central nervous system. In recent years the development of new drugs that have been shown to modify the natural history of MS have had a substantial impact on the treatment of the disease. Aims. To harmonise and integrate the evidence available on optimising the treatment of patients with MS. Development. In order to fulfil our main aim, a group of experts from different Latin American countries drew lip a list of statements related to the use of immunomodulatory agents in the different clinical forms of the disease and the strategies that should be considered in cases in which the therapeutic response was suboptimal. Each of the participants used a structured scale to express the extent to which he or she agreed or disagreed, and a consensus was considered to have been reached when acceptance of each of the statements was equal to or higher than 80%. Conclusions. These recommendations will provide neurologists with the tools needed to make decisions that optimise the treatment of MS patients.en
dc.description.affiliationHosp Italiano Buenos Aires, Serv Neurol, Ctr Esclerosis Multiple, RA-1181 Buenos Aires, DF, Argentina
dc.description.affiliationFLENI, Inst Invest Neurol Dr Raul Carrea, Buenos Aires, DF, Argentina
dc.description.affiliationIMSS, Hosp Especialidades, Puebla, Mexico
dc.description.affiliationUniv Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, Brazil
dc.description.affiliationHosp Domingo Luciani, Caracas, Venezuela
dc.description.affiliationIMSS, Ctr Med Occidente, Dept Neurol, Guadalajara, Jalisco, Mexico
dc.description.affiliationHosp San Jose de Bogota, Serv Neurol, Bogota, Colombia
dc.description.affiliationBaylor Coll Med, Houston, TX 77030 USA
dc.description.affiliationUnifespUniv Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent494-498
dc.identifierhttp://www.neurologia.com/sec/resumen.php?or=web&i=e&id=2006466
dc.identifier.citationRevista De Neurologia. Barcelona: Revista De Neurologia, v. 44, n. 8, p. 494-498, 2007.
dc.identifier.issn0210-0010
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/45466
dc.identifier.wosWOS:000246273200009
dc.language.isospa
dc.publisherRevista De Neurologia
dc.relation.ispartofRevista De Neurologia
dc.rightsAcesso restrito
dc.subjectimmunomodulatorsen
dc.subjectmitoxantroneen
dc.subjectmultiple sclerosisen
dc.subjectneutralising antibodiesen
dc.subjecttherapeutic failureen
dc.subjecttreatmenten
dc.titleRecommendations for optimising the treatment of multiple sclerosis in Latin Americaen
dc.titleRecomendaciones para la optimización del tratamiento de la esclerosis múltiple en Latinoaméricaes
dc.typeArtigo
Arquivos
Coleções